2,051 Shares in Stryker Corporation (SYK) Purchased by Bourgeon Capital Management LLC
Bourgeon Capital Management LLC acquired a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,051 shares of the medical technology company’s stock, valued at approximately $285,000.
Several other large investors have also recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Stryker Corporation by 5.2% during the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock worth $3,083,382,000 after acquiring an additional 1,161,688 shares during the period. BlackRock Inc. boosted its holdings in shares of Stryker Corporation by 2,526.4% during the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock worth $2,893,242,000 after acquiring an additional 21,140,000 shares during the period. Fundsmith LLP boosted its holdings in shares of Stryker Corporation by 4.6% during the first quarter. Fundsmith LLP now owns 5,175,453 shares of the medical technology company’s stock worth $681,348,000 after acquiring an additional 226,057 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Stryker Corporation by 0.5% during the first quarter. Wellington Management Group LLP now owns 4,569,118 shares of the medical technology company’s stock worth $601,525,000 after acquiring an additional 24,139 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Stryker Corporation by 6.3% during the first quarter. Geode Capital Management LLC now owns 2,786,406 shares of the medical technology company’s stock worth $366,255,000 after acquiring an additional 166,133 shares during the period. Institutional investors own 74.18% of the company’s stock.
A number of equities research analysts have recently issued reports on the company. Cowen and Company restated a “buy” rating and set a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a report on Sunday, July 30th. BidaskClub upgraded Stryker Corporation from a “hold” rating to a “buy” rating in a report on Thursday, August 17th. Zacks Investment Research cut Stryker Corporation from a “buy” rating to a “hold” rating in a report on Thursday, August 17th. Oppenheimer Holdings, Inc. set a $148.00 price objective on Stryker Corporation and gave the stock a “hold” rating in a report on Friday, July 28th. Finally, Royal Bank Of Canada boosted their price objective on Stryker Corporation from $140.00 to $155.00 and gave the stock an “outperform” rating in a report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. Stryker Corporation has a consensus rating of “Hold” and an average target price of $145.73.
In other news, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $146.26, for a total transaction of $164,396.24. Following the completion of the sale, the insider now directly owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider David Floyd sold 19,305 shares of Stryker Corporation stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $144.56, for a total transaction of $2,790,730.80. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,429 shares of company stock valued at $3,686,927. Insiders own 7.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “2,051 Shares in Stryker Corporation (SYK) Purchased by Bourgeon Capital Management LLC” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was illegally stolen and reposted in violation of international copyright and trademark law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/12/2051-shares-in-stryker-corporation-syk-purchased-by-bourgeon-capital-management-llc.html.
Shares of Stryker Corporation (NYSE SYK) opened at 143.69 on Tuesday. The company has a market capitalization of $53.75 billion, a PE ratio of 32.07 and a beta of 0.81. Stryker Corporation has a 1-year low of $106.48 and a 1-year high of $148.84. The firm’s 50-day moving average price is $144.00 and its 200 day moving average price is $138.33.
Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion during the quarter, compared to the consensus estimate of $2.98 billion. During the same period last year, the firm earned $1.39 EPS. The business’s quarterly revenue was up 6.1% compared to the same quarter last year. Equities analysts predict that Stryker Corporation will post $6.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, October 31st. Shareholders of record on Friday, September 29th will be issued a $0.425 dividend. This represents a $1.70 annualized dividend and a yield of 1.18%. The ex-dividend date is Thursday, September 28th. Stryker Corporation’s payout ratio is 37.95%.
Stryker Corporation Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Stock Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related stocks with our FREE daily email newsletter.